(VIANEWS) – Celsius Holdings (CELH), Tidewater (TDW), Insulet (PODD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Celsius Holdings (CELH)
77.6% sales growth and 16.18% return on equity
Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional drinks and liquid supplements in the United States and internationally. The company offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name. It also provides CELSIUS On-the-Go, a powdered form of the active ingredients in functional energy drinks in individual On-The-Go packets and canisters; and sparkling grapefruit, cucumber lime, and orange pomegranate, as well as pineapple coconut, watermelon berry, and strawberries and cream non-carbonated functional energy drinks under the CELSIUS Sweetened name; and CELSIUS ready-to drink products. It distributes its products through direct-to-store delivery distributors and direct to retailers, include supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, spas, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.48.
PE Ratio
Celsius Holdings has a trailing twelve months price to earnings ratio of 106.81. Meaning, the purchaser of the share is investing $106.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.18%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 233.3% and 46.2%, respectively.
2. Tidewater (TDW)
69.8% sales growth and 7.29% return on equity
Tidewater Inc., together with its subsidiaries, provides offshore support vessels and marine support services to the offshore energy industry through the operation of a fleet of marine service vessels worldwide. It provides services in support of offshore crude oil and natural gas exploration, field development, and production, as well as windfarm development and maintenance, including towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction, and seismic and subsea support; geotechnical survey support for windfarm construction; and various specialized services, such as pipe and cable laying. The company operates anchor handling towing supply vessels, platform supply vessels, crew boats, utility vessels, and offshore tugs. The company serves oil and natural gas exploration, field development, and production companies; mid-sized and smaller independent exploration and production companies; foreign government-owned or government-controlled organizations, and other related companies; drilling contractors; and other companies, such as offshore construction, windfarm development, diving, and well stimulation companies. Tidewater Inc. was incorporated in 1956 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Tidewater has a trailing twelve months EPS of $1.4.
PE Ratio
Tidewater has a trailing twelve months price to earnings ratio of 41.26. Meaning, the purchaser of the share is investing $41.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.29%.
Yearly Top and Bottom Value
Tidewater’s stock is valued at $57.77 at 09:22 EST, way below its 52-week high of $73.55 and way above its 52-week low of $28.14.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 270% and 269.6%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 56.1%, now sitting on 894.07M for the twelve trailing months.
Previous days news about Tidewater(TDW)
- Implied volatility surging for tidewater (tdw) stock options. According to Zacks on Wednesday, 29 November, "Given the way analysts feel about Tidewater right now, this huge implied volatility could mean there’s a trade developing. ", "Investors in Tidewater Inc. (TDW Quick QuoteTDW – Free Report) need to pay close attention to the stock based on moves in the options market lately. "
3. Insulet (PODD)
23.6% sales growth and 23.18% return on equity
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Earnings Per Share
As for profitability, Insulet has a trailing twelve months EPS of $1.73.
PE Ratio
Insulet has a trailing twelve months price to earnings ratio of 110.78. Meaning, the purchaser of the share is investing $110.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.18%.
Previous days news about Insulet(PODD)
- According to Zacks on Tuesday, 28 November, "While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). "
- According to Zacks on Tuesday, 28 November, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Insulet (PODD Quick QuotePODD – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). "
- According to Zacks on Wednesday, 29 November, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Insulet (PODD Quick QuotePODD – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). "
- According to Zacks on Wednesday, 29 November, "While Insulet presently sports a Zacks Rank #1 (Strong Buy), DexCom carries a Zacks Rank #2. "
- According to Zacks on Wednesday, 29 November, "Some better-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Insulet (PODD Quick QuotePODD – Free Report) and DexCom (DXCM Quick QuoteDXCM – Free Report) . ", "While Haemonetics and DexCom carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). "
4. Texas Roadhouse (TXRH)
12% sales growth and 28.45% return on equity
Texas Roadhouse, Inc., together with its subsidiaries, operates casual dining restaurants in the United States and internationally. The company operates and franchises Texas Roadhouse and Bubba's 33 restaurants. As of December 29, 2020, it operated 537 domestic restaurants and 97 franchise restaurants. Texas Roadhouse, Inc. was founded in 1993 and is based in Louisville, Kentucky.
Earnings Per Share
As for profitability, Texas Roadhouse has a trailing twelve months EPS of $4.35.
PE Ratio
Texas Roadhouse has a trailing twelve months price to earnings ratio of 25.73. Meaning, the purchaser of the share is investing $25.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.45%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Texas Roadhouse’s EBITDA is 1.82.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 20.2% and 14.1%, respectively.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Dec 4, 2023, the estimated forward annual dividend rate is 2.2 and the estimated forward annual dividend yield is 1.97%.
Volume
Today’s last reported volume for Texas Roadhouse is 812824 which is 11.98% below its average volume of 923455.
5. Yelp (YELP)
10% sales growth and 12.76% return on equity
Yelp Inc. operates a platform that connects consumers with local businesses in the United States and internationally. The company's platform covers various local business categories, including restaurants, shopping, beauty and fitness, health, and other categories, as well as home, local, auto, professional, pets, events, real estate, and financial services. It provides free and paid advertising products to businesses, which include cost-per-click search advertising and multi-location Ad products, as well as enables businesses to deliver targeted search advertising to local audiences; and business listing page products. The company also offers other services comprising Yelp Guest Manager, a subscription-based suite of front-of-house management tools for restaurants, nightlife and certain other venues, which include online reservations, a waitlist management solution that allows consumers to check wait times and join waitlists remotely as well as through hostless kiosks, and seating and server rotation management tools; Yelp Knowledge program that offers business owners local analytics and insights through access to its historical data and other proprietary content; and Yelp Fusion, which offers free and paid access to content and data for consumer-facing enterprise use through publicly available APIs. In addition, it provides content licensing, as well as allows third-party data providers to update and manage business listing information on behalf of businesses. Further, the company offers its products directly through its sales force; indirectly through partners; and online through its website and business app, as well as non-advertising partner arrangements. It has partnership with Grubhub for providing consumers with a service to place food orders for pickup and delivery. The company was incorporated in 2004 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, Yelp has a trailing twelve months EPS of $1.26.
PE Ratio
Yelp has a trailing twelve months price to earnings ratio of 34.68. Meaning, the purchaser of the share is investing $34.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.76%.
Sales Growth
Yelp’s sales growth is 10.4% for the current quarter and 10% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 50% and 1050%, respectively.
6. LeMaitre Vascular (LMAT)
7.1% sales growth and 9.92% return on equity
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, LeMaitre Vascular has a trailing twelve months EPS of $1.22.
PE Ratio
LeMaitre Vascular has a trailing twelve months price to earnings ratio of 43.63. Meaning, the purchaser of the share is investing $43.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.92%.
Moving Average
LeMaitre Vascular’s value is above its 50-day moving average of $52.02 and below its 200-day moving average of $56.41.
7. Universal Health Services (UHS)
5.7% sales growth and 11.15% return on equity
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Universal Health Services has a trailing twelve months EPS of $9.52.
PE Ratio
Universal Health Services has a trailing twelve months price to earnings ratio of 14.28. Meaning, the purchaser of the share is investing $14.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.15%.
Yearly Top and Bottom Value
Universal Health Services’s stock is valued at $135.96 at 09:22 EST, way under its 52-week high of $158.57 and way above its 52-week low of $113.69.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 29, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.59%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Universal Health Services’s EBITDA is 1.04.
Moving Average
Universal Health Services’s value is above its 50-day moving average of $127.32 and higher than its 200-day moving average of $135.12.
